Xcout IntelDay One Biopharmaceuticals competitors & alternatives
The 12 closest competitors and alternatives to Day One Biopharmaceuticals among life sciences & healthcare companies — ranked by similarity to what Day One Biopharmaceuticals actually does, not by market-cap band.
Subscribe to see Day One Biopharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cancer therapies, with a focus on diseases affecting children and adults. Its lead product, tovorafenib (Ojemda), is an FDA-approved treatment for pediatric patients with relapsed or refractory low-grade glioma harboring qualifying BRAF alterations.
Recent Day One Biopharmaceuticals news
Top 12 Day One Biopharmaceuticals competitors
Ranked by semantic similarity — how close each company is to Day One Biopharmaceuticals by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Treovir is a clinical-stage biotechnology company that develops therapies for pediatric brain tumors. Its lead product candidate, G207, is an oncolytic virus therapy currently undergoing clinical trials to treat conditions such as pediatric recurrent glioblastoma.
Biotechnology
Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.
Biotech
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Biotechnology
Ayala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Monmouth Junction, New Jersey. The company focuses on developing targeted therapeutics for rare tumors and aggressive cancers. It engages in clinical research and asset management within the biotechnology and pharmaceutical sector.
Biotechnology
Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.
Biotech
Fore Biotherapeutics is a virtual precision oncology company rooted in science and innovation, with expertise and talent across the USA. The company is focused on developing treatments, including its Plixorafenib Program.
Biotechnology
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
Biotechnology
Revolution Medicines is a clinical-stage oncology company that develops novel targeted therapies to outsmart cancer. The company focuses on discovering and advancing therapeutic pipelines for patients with difficult-to-treat tumors.
Biotechnology
G1 Therapeutics, Inc. is a commercial-stage oncology and biopharmaceutical company focused on developing next-generation therapies to improve outcomes for cancer patients undergoing chemotherapy.
Biotechnology
DeuterOncology is a clinical-stage drug development company that designs and develops deuterated MET kinase inhibitors as targeted therapies for lung cancer and other advanced solid tumors. Its lead product, DO-2, is a selective, brain-penetrant MET kinase inhibitor intended to improve tolerability and reduce toxicity compared to existing treatments.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Biotechnology
Orbus Therapeutics, Inc. is a pharmaceutical company headquartered in Menlo Park, California, dedicated to developing treatments for rare forms of cancer, including clinical trials for brain tumors.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Day One Biopharmaceuticals and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Day One Biopharmaceuticalsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →